8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 16, 2007

Shire plc

(Exact name of registrant as specified in its charter)

England and Wales

 (State or other jurisdiction of incorporation)

0-29630	98-0484822
(Commission File Number)	(IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,

Hampshire RG24 8EP England

 (Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               44 1256 894 000

 (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

Shire plc has issued the press releases attached as Exhibit 99.01, Exhibit 99.02 and Exhibit 99.03 which are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibits are filed herewith:

99.01Press Release dated April 16, 2007

99.02Press Release dated April 16, 2007

99.03Press Release dated April 17, 2007

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant  has duly caused  this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC
By:	/s/ A C Russell
	Name: Angus Russell
	Title:    Chief Financial Officer

Dated: April 17, 2007

EXHIBIT INDEX
Number	Description
99.01	Press Release dated April 16, 2007
99.02	Press Release dated April 16, 2007
99.03	Press Release dated April 17, 2007

EX-99.1

EXHIBIT 99.01

Hampshire International Business Park Chineham  Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

Results of Extraordinary General Meeting held on 16 April 2007

Shire plc (LSE: SHP.L; NASDAQ: SHPGY; TSX: SHQ) ("Shire" or the "Company") announced today that its shareholders approved the proposed acquisition of New River Pharmaceuticals Inc. (NASDAQ: NRPH) ("New River") at the Shire Extraordinary General Meeting held on 16 April 2007. The approval by Shire’s shareholders satisfies one of the conditions to the tender offer by Shire’s wholly owned subsidiary for all outstanding shares of New River common stock at a price of $64.00 per share, or approximately $2.6 billion in total for the fully diluted equity interest of New River. Consummation of the tender offer now remains subject only to certain customary conditions, including the valid tender of a majority of the outstanding New River shares on a fully diluted basis.

The tender offer will expire at 12:00 Midnight, New York City time, on Tuesday, April 17, 2007. The tender offer is being made pursuant to the previously announced agreement of merger among Shire, its wholly owned subsidiary and New River.

At the Extraordinary General Meeting, a resolution to approve the New River acquisition and to sanction an increase in the total borrowings of the Shire group of companies was passed on a show of hands. The following is the text of the resolution:

Text of Resolution

“That:

(A) in accordance with Article 101 of the Company’s articles of association, notwithstanding the limit of $1.2 billion on the maximum aggregate amount of the monies borrowed by the group (within the meaning of Article 101), the directors be authorised to permit the maximum aggregate amount of monies borrowed by the group (within such meaning) to exceed, at any time, $1.2 billion provided that they shall not exceed $4 billion; and

(B) the Acquisition (as defined in the circular to shareholders of the Company dated 26 March 2007 (the “Circular”)) upon the terms and conditions set out in the Merger Agreement (as defined in the Circular), with any amendments, modifications, improvements, variations or revisions thereto which are not of a material nature, be and is hereby approved and the directors of the Company (or a duly authorised committee of thereof) be and are hereby authorised to do all such things and execute all

such agreements and make such arrangements as may seem to them necessary, expedient or appropriate to give effect to the Acquisition.”

The proxy votes received for the meeting are set out below:

For*	Against	Abstentions**
434,133,245	16,484	109,890

* These figures include discretionary votes

** Abstentions are not counted in the proportion of votes “for” or “against

A copy of this resolution has been provided to the Financial Services Authority for publication through the document viewing facility.

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252
Media	Jessica Mann (Rest of the World)	+44 1256 894 280
	Matthew Cabrey (North America)	+1 484 595 8248

Notes to editors

Additional Information

This press release is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell New River common stock. The tender offer is being made pursuant to a tender offer statement on Schedule TO (including the offer to purchase, letter of transmittal and other related tender offer materials, which were mailed to New River’s shareholders) filed by a subsidiary of Shire with the Securities and Exchange Commission (“SEC”) on March 2, 2007. In addition, on March 2, 2007, New River filed with the SEC a solicitation/recommendation statement on Schedule 14D-9 with respect to the tender offer, which was mailed to New River’s shareholders. The tender offer statement (and related materials), as it may be amended from time to time, and the solicitation/recommendation statement, as it may be amended from time to time, contain important information, including the various terms of, and conditions to, the tender offer, that should be read carefully before any decision is made with respect to the tender offer. These materials may be obtained free of charge by contacting the information agent for the tender offer, Innisfree M&A Incorporated, at (888) 750-5834 (toll-free from the U.S. or Canada) or (412) 232-3651 (toll-free from outside the U.S. and Canada). In addition, all of these materials (and all other materials filed by New River and Shire with the SEC) are available for free at the website maintained by the SEC at www.sec.gov.

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire’s Attention Deficit and Hyperactivity Disorder (ADHD) franchise; patents, including but not limited to, legal challenges relating to Shire’s ADHD franchise; government regulation and approval, including but not limited to the expected product approval dates of SPD503 (guanfacine extended release) (ADHD) and SPD465 (extended release triple-bead mixed amphetamine salts) (ADHD); Shire’s ability to secure new products for commercialization and/or development; Shire’s ability to consummate and benefit from its proposed acquisition of New River Pharmaceuticals Inc.; and other risks and uncertainties detailed from time to time in Shire plc’s filings with the Securities and Exchange Commission, particularly Shire plc’s Annual Report on Form 10-K for the year ended December 31, 2006.

Registered in England 2883758 Registered Office as above

EX-99.2

EXHIBIT 99.02

Hampshire International Business Park Chineham  Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

Notification of major interests in shares

16 April 2007

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ)

2. Reason for the notification	State Yes/No
An acquisition or disposal of voting rights	Yes
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An event changing the breakdown of voting rights
Other (please specify):

3. Full name of person(s) subject to the notification obligation:	Dr. Barry Price (proxy holder)
4. Full name of shareholder(s) (if different from 3.):	Shareholders appointing Dr. Barry Price as discretionary proxy holder
5. Date of the transaction (and date on which the threshold is crossed or reached if different):	14 April 2007
6. Date on which issuer notified:	16 April 2007
7. Threshold(s) that is/are crossed or reached:	22%
8. Notified details:

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE	Situation previous to the Triggering transaction		Resulting situation after the triggering transaction
	Number of  Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights
			Direct	Direct	Indirect	Direct	Indirect
	31,350	31,350	122,308,855	31,350	122,277,505	0.06	22.98

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument Expiration date Exercise/Conversion Period/ Date Number of voting rights that may be acquired if the instrument is exercised/converted % of voting rights

Total (A+B)
Number of voting rights	% of voting rights
122,308,855	22.04

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

Proxy Voting:

10. Name of the proxy holder:	Dr. Barry Price
11. Number of voting rights proxy holder will cease to hold:	122,277,505
12. Date on which proxy holder will cease to hold voting rights:	17 April 2007

13. Additional information:	When proxy expires, % of voting rights will return to the shareholders that appointed Dr. Barry Price as discretionary proxy
14. Contact name:	Vivienne Hemming, Deputy Company Secretary Shire plc
15. Contact telephone number:	+ 44 1256 894276

Annex Notification Of Major Interests In Shares

A: Identity of the person or legal entity subject to the notification obligation

Full name (including legal form for legal entities)

Contact address (registered office for legal entities)

Phone number

Other useful information (at least legal representative for legal persons)

B: Identity of the notifier, if applicable
Full name	Dr. Barry Price
Contact address	Shire plc Hampshire International Business Park, Chineham Basingstoke Hampshire RG24 8EP
Phone number	+44 1256 894 276
Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)	Dr. Barry Price is a Senior Non Executive Director of Shire plc

C:Additional information

This notification is being made because Dr. Barry Price, as Chairman of the meeting has been granted discretionary proxy for the EGM held on 16 April 2007.

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through

acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above

EX-99.3

EXHIBIT 99.03

Hampshire International Business Park Chineham  Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

FIRST QUARTER 2007 RESULTS DATE NOTIFICATION

25 April 2007

Basingstoke, UK and Philadelphia, US – April 17, 2007 – Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) will announce first quarter 2007 earnings on Wednesday 25 April 2007.

Results press release will be issued at:	12:00 BST / 07:00 EDT
Investor conference call time:	14:00 BST / 09:00 EDT

Live conference call for investors:

Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the live conference call for investors at 14:00 BST/9:00 EDT.

Please RSVP ssalah@shire.com (T: +44 (0)1256 894 160) for this conference call.

The details of the live conference call are as follows:

UK dial in	0800 953 0936
US dial in	1866 224 2972
International dial in	+44 (0) 1452 568 061
Password/Conf ID	5717753#

Live Webcast:

The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investors section. A slide presentation to accompany the call will also be available on the Shire website.

Replay:

A replay of the presentation will be available for two weeks. Details are as follows:

UK dial in	0800 953 1533 / 0845 245 5205
US dial in	1866 247 4222
International dial in	+44 (0) 1452 55 00 00
Pin code	5717753#
Webcast replay	www.shire.com, in the investors section

For further information please contact:

Investor Relations	Souheil Salah (Rest of the World)	+44 1256 894 160
	Heidi Wunder (North America)	+1 484 595 8970

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com

Registered in England 2883758 Registered Office as above